|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
|
26715116 |
2015 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aberrant β-catenin activation contributes to a third or more of human hepatocellular carcinoma (HCC), but β-catenin activation alone is not sufficient to induce liver cancer in mice.
|
25661872 |
2015 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consistent with its enrichment for CTNNB1 mutations (69%), lncRNA profile of the CTNNB1-enriched EEC subgroup was highly similar to that of the CTNNB1-enriched liver cancer subgroup.
|
26431491 |
2015 |
|
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The purposed of this study was to determine whether FH535, which was previously shown to block the β-catenin pathway, could inhibit β-catenin activation of target genes and inhibit proliferation of Liver Cancer Stem Cells (LCSC) and HCC cell lines.
|
24940873 |
2014 |
|
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples.
|
24837480 |
2014 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results validate β-catenin as a target for liver cancer therapy and demonstrate the promise of RNAi in general and DsiRNAs in particular for reaching traditionally undruggable cancer targets.
|
24089139 |
2014 |
|
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our study uncovers a regulatory mechanism underlying liver cancer-specific Wnt transcriptional output, and suggests that TRIB2 functions as a signaling nexus to integrate the Wnt/β-catenin, Hippo/YAP, and C/EBPα pathways in cancer cells.
|
23769673 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor suppressor function of ezrin-radixin-moesin-binding phosphoprotein-50 through β-catenin/E-cadherin pathway in human hepatocellular cancer.
|
23483729 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.
|
23555187 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BrMC can inhibit the functions and characteristics of LCSCs derived from the liver cancer MHCC97 cell line through downregulation of β-catenin expression.
|
24431896 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results also indicated that AR cells increased abundantly in Tbx3, a downstream target of Wnt/β-catenin that it is implicated in liver cancer.
|
24317053 |
2013 |
|
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Wnt-pathway was assessed using mRNA (642 HCCs and 21 liver cancer cell lines) and miRNA expression data (89 HCCs), immunohistochemistry (108 HCCs), and CTNNB1-mutation data (91 HCCs).
|
22811581 |
2012 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
CTD_human |
Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen.
|
21047994 |
2011 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also investigated beta-catenin pathway activation in two liver cancer cell lines, HuH-6 and HuH-7.
|
21992464 |
2011 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
|
19101982 |
2009 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the importance of CCND1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis, we investigated the genetic interactions between CCND1, beta-catenin, and c-Met in liver cancer development using mouse models.
|
19118010 |
2009 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We frequently detected the active form of beta-catenin and accumulation of nuclear beta-catenin in liver cancer cell lines.
|
18592156 |
2008 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study confirms that beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer.
|
17962810 |
2008 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
|
17283120 |
2007 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, we identified a number of candidate Wnt/beta-catenin target genes that can be useful for studying the role of altered Wnt signaling in liver cancer development, and showed that some of them might be direct targets of Wnt signaling in hepatoma cells.
|
17157329 |
2007 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.
|
17030191 |
2006 |
|
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human hepatocellular cancers (HCC) lack RAS mutations but are frequently mutated in CTNNB1, the human Catnb ortholog.
|
15965925 |
2005 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/beta-catenin activation is observed in normal liver development, regeneration, and liver cancer.
|
16012954 |
2005 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The beta-catenin mutations are identified in up to 30% of HCC and 80% of hepatoblastoma, suggesting a potential role of beta-catenin in the pathogenesis of liver cancers.
|
14767485 |
2004 |
|
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the EBP50/beta-catenin complex promotes Wnt signaling, and over-expression of EBP50 may work cooperatively with beta-catenin in the development of liver cancer.
|
12830000 |
2003 |